| Mode | Project ID | Indication | Hit Generation | Hit to Lead | Lead Optimization | IND-Enabling | Phase 1 | |
|---|---|---|---|---|---|---|---|---|
| Activator | PTT-001 | I-O | ||||||
| PTT-009 | I-O | |||||||
| PTT-007 | I-O | |||||||
| Gene Modulation | PTT-008 | I-O | ||||||
| Inhibitor | PTT-003 | Chemotherapy Associated Adverse Effect such as CIPN CNS Diseases Kidney Diseases Atherosclerosis |
||||||
| PTT-004,005 | Gain function auto-inflammatory Diseases IBD |
|||||||
| PTT-002 | Sepsis | |||||||
| PTT-006 | Asthma | |||||||
| PTT-001 | I-O | |
| PTT-009 | I-O | |
| PTT-007 | I-O | |
| PTT-008 | I-O | |
| PTT-003 | Chemotherapy Associated Adverse Effect such as CIPN CNS Diseases Kidney Diseases Atherosclerosis |
|
| PTT-004,005 | Gain function auto-inflammatory Diseases IBD |
|
| PTT-002 | Sepsis | |
| PTT-006 | Asthma | |